CYP19A1 and breast carcinoma: Mutations in the ESR1 ligand-binding domain are the principal feature of hormone receptor-positive metastatic breast cancer, arising in response to aromatase inhibition and allowing the tumor to progress in the absence of estrogen [67,68].